Abstract
Purpose
Thyroid cancer (TC), the most common endocrine malignancy, increases its incidence worldwide. MicroRNAs have been shown to be abnormally expressed in tumors and could represent valid diagnostic markers for patients affected by TC. Our aim was to analyze the expression of tumorsuppressor hsa-let7b-5p and hsa-let7f-5p, together with their predicted targets SLC5A5 (NIS) and HMGA2, in papillary (PTC), follicular (FTC) and anaplastic (ATC).
Methods
8 FTC, 14 PTC, 12 ATC and three normal thyroid tissue samples were analyzed for the expression of pre-let7b, hsa-let7b-5p and hsa-let7f-5p as SLC5A5 and HMGA2 by RT-qPCR. Data were analyzed by REST 2008.
Results
FTC patients showed a significant down-regulation of hsa-let7b-5p and its precursor. hsa-let7f-5p was overexpressed, and SLC5A5 was strongly suppressed. HMGA2 was overexpressed, reflecting no correlation with its regulatory let7 miRNAs. PTC samples were characterized by up-regulation of hsa-let7b-5p, its precursor and hsa-let7f-5p. SLC5A5 was strongly suppressed in comparison with normal thyroid tissue. HMGA2 was overexpressed, as shown in FTC, also. ATC samples showed a similar miRNAs profile as PTC. In contrast with FTC and PTC, these patients showed a stable or up-regulated SLC5A5 and HMGA2.
Conclusions
Expression of HMGA2 is not correlated with the regulatory let7 miRNAs. Interestingly, SLC5A5 was down-regulated in FTC and PTC. Its expression could be modulated by hsa-let-7f-5p. ATC showed a loss of SLC5A5/hsa-let7f-5p correlation. SLC5A5, in ATC, needs further investigation to clarify the genetic/epigenetic mechanism altering its expression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baldan F, Mio C, Allegri L, Puppin C, Russo D, Filetti S, Damante G (2015) Synergy between HDAC and PARP inhibitors on proliferation of a human anaplastic thyroid cancer-derived cell line. Int J Endocrinol 2015:978371. doi:10.1155/2015/978371
Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866. doi:10.1038/nrc1997
Chiappetta G et al (2008) HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 44:1015–1021. doi:10.1016/j.ejca.2008.02.039
Choi YW et al (2014) B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1. Exp Mol Med 46:e120. doi:10.1038/emm.2014.68
Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502–511. doi:10.1056/NEJMra072367
Di Fazio P et al (2012) Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res 318:1832–1843. doi:10.1016/j.yexcr.2012.04.018
Dohan O, Carrasco N (2003) Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213:59–70. doi:10.1016/j.mce.2003.10.059
Dohan O et al (2003) The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24:48–77. doi:10.1210/er.2001-0029
Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M (1999) Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141:443–457. doi:10.1530/eje.0.1410443
Gottardo F et al (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392. doi:10.1016/j.urolonc.2007.01.019
Hsu KT et al (2014) Novel approaches in anaplastic thyroid cancer therapy. Oncologist 19:1148–1155. doi:10.1634/theoncologist.2014-0182
Jang S et al (2015) Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation. Cancer Gene Ther 22:410–416. doi:10.1038/cgt.2015.37
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
Jin L et al (2011) HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR. Diagn Mol Pathol 20:71–80. doi:10.1097/PDM.0b013e3181ed784d
Keutgen XM et al (2012) A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 18:2032–2038. doi:10.1158/1078-0432.CCR-11-2487
Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ (2015) Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 100:E253–E261. doi:10.1210/jc.2014-3101
Lakshmanan A, Wojcicka A, Kotlarek M, Zhang X, Jazdzewski K, Jhiang SM (2015) microRNA-339-5p modulates Na+/I− symporter-mediated radioiodide uptake. Endocr Relat Cancer 22:11–21. doi:10.1530/ERC-14-0439
Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A (2010) HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol 118:287–297. doi:10.1002/cncy.20095
Li L et al (2015) Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression. Biochem Biophys Res Commun 462:314–321. doi:10.1016/j.bbrc.2015.04.134
Liang JA, Chen CP, Huang SJ, Ho TY, Hsiang CY, Ding HJ, Wu SL (2005) A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma. Cancer Lett 230:65–71. doi:10.1016/j.canlet.2004.12.036
Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, Ai K (2014) H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumour Biol 35:9163–9169. doi:10.1007/s13277-014-2185-5
Madison BB, Jeganathan AN, Mizuno R, Winslow MM, Castells A, Cuatrecasas M, Rustgi AK (2015) Let-7 represses carcinogenesis and a stem cell phenotype in the intestine via regulation of Hmga2. PLoS Genet 11:e1005408. doi:10.1371/journal.pgen.1005408
Marini F, Luzi E, Brandi ML (2011) MicroRNA role in thyroid cancer development. J Thyroid Res 2011:407123. doi:10.4061/2011/407123
Mayr C, Hemann MT, Bartel DP (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315:1576–1579. doi:10.1126/science.1137999
Ngamphaiboon N et al (2015) A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Invest New Drugs 33:225–232. doi:10.1007/s10637-014-0174-6
Pallante P, Sepe R, Puca F, Fusco A (2015) High mobility group a proteins as tumor markers. Front Med (Lausanne) 2:15. doi:10.3389/fmed.2015.00015
Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212. doi:10.1155/2013/965212
Ricarte-Filho JC, Fuziwara CS, Yamashita AS, Rezende E, da-Silva MJ, Kimura ET (2009) Effects of let-7 microRNA on cell growth and differentiation of papillary thyroid cancer. Transl Oncol 2:236–241
Wapnir IL et al (2003) Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 88:1880–1888. doi:10.1210/jc.2002-021544
Weinlander E et al (2014) The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. J Surg Res 190:191–197. doi:10.1016/j.jss.2014.02.042
Zhang L et al (2015) Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget 6:9073–9085
Acknowledgments
SE was supported by a grant from Kempkes Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Alexander I. Damanakis and Sabine Eckhardt have contributed equally to this article.
Rights and permissions
About this article
Cite this article
Damanakis, A.I., Eckhardt, S., Wunderlich, A. et al. MicroRNAs let7 expression in thyroid cancer: correlation with their deputed targets HMGA2 and SLC5A5. J Cancer Res Clin Oncol 142, 1213–1220 (2016). https://doi.org/10.1007/s00432-016-2138-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2138-z